您确实想关闭吗？
除非您已经将产品添加到购物车或收藏夹中，否则关闭操作不会保存您的定制内容。
单击“确认”以关闭MILLIPLEX® MAP工具，或单击“取消”以返回您的选择。
选择可定制的板面及预混试剂盒 - 或者 - 细胞信号试剂盒MAPmates™
设计您的MILLIPLEX® MAP试剂盒并定价。
可定制的板面及预混试剂盒
我们范围广泛的产品组合包括多元板面，允许您在板面中选择最符合您需求的分析物。在一个单独的选项卡上，您可以选择预混的细胞活素型或单试剂盒。
细胞信号试剂盒和MAPmates™
选择允许您探索整个路径或流程的固定试剂盒。或者通过选择单试剂MAPmates™，按照所提供的指南来设计您自己的试剂盒。
下列MAPmates™不应复合（plex）在一起：
-需要另一种 化验缓冲液的 MAPmates™。
-磷特异性和总MAPmate™对，例如总GSK3β和GSK3β（Ser 9）。
-PanTyr和现场特异性MAPmates™，例如磷-EGF受体和磷-STAT1（Tyr701）。
-单个靶多个磷-MAPmate™（Akt, STAT3）。
-GAPDH和β-微管蛋白不能与含有panTyr的试剂盒或MAPmates™复合（plex）在一起。
| 产品目录编号 | 订购说明 | 数量 / 包装 | 清单 |
该产品已添加到收藏夹。
| 选择品种 | . |
| 选择板面类型 | . |
| 选择试剂盒 | . |
| 选择样品类型 | 对于某些板面，样品类型将决定可以将哪些分析物复合（plex）在一起。 |
从我们的多元板面中选择可用的分析物，或者从预混或单试剂盒中选择。
设计您自己的试剂盒，或者从我们预先混合的板面或单工板面中选择。
Custom Premix
Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
| Catalogue Number | Ordering Description | Qty/Pack | List |
该产品已添加到收藏夹。
此产品已添加到您的购物车。
现在您可以定制另一个试剂盒了，您可选择预混试剂盒，结帐或关闭订购工具。
Pharma and Biopharma Manufacturing Webinars
Browse Our On-Demand Webinars:
Register Today for Our Upcoming Webinars
Take part in our complimentary, live webinars, where you’ll interact with experts who are breaking ground in the pharmaceutical and biopharmaceautical industries. You’ll learn about the newest tools and technologies while gathering valuable tips and troubleshooting strategies for the applications most relevant to your processes.
Find an upcoming webinar below and register today!
Reducing Risk and Decreasing Timelines for Biopharmaceutical Cell Line Development Through Optimized Reagents and Processes
|
Abstract: Join us to learn about challenges faced with traditional expression systems and how a CHO cell line with the glutamine synthetase knock-out via ZFN provides benefits for fast, efficient cell line development with stable and high titer expression. CHO cells with their unique characteristics, represent the major expression system within the biopharmaceutical industry. However, one of the major challenges in cell line development is to identify those rare, high-producing clones in a huge population of non-expressing or low-expressing cell lines. This leads to laborious and time consuming cell line development processes. This webinar will educate the audience about challenges faced with traditional expression systems and how the CHO cell line with the glutamine synthetase knock-out via Zinc Finger Nucleases provides benefits for fast and efficient cell line development as well as stable and high titer expression. We will explore additional cell line engineering targets that can be modified to engineer a cell line that mitigates risks and removes bottlenecks throughout the biopharmaceutical process. In this webinar, you will learn:
|
A Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
|
Abstract: Every biopharma executive must make important decisions early in clinical development that will impact their molecule’s journey – and ultimately the success of their commercial strategy. The key to this success is to make the right decisions at the right time. In this webinar, our experts share some key considerations to help biopharmaceutical companies successfully advance a molecule from the laboratory to the clinic as quickly as possible without sacrificing product quality, process efficiency, or patient safety. To achieve this goal, companies must navigate the complexities associated with business planning, cell line development, process development, technology, and regulatory and risk assessment. In this webinar, you will learn:
|
Comprehensive Assessment of a Stimulus-Responsive Flocculation Polymer for Cell Culture Clarification
|
Abstract: This webinar will provide a comprehensive, holistic assessment of the effects of Clarisolve® mPAA flocculation polymer pre-treatment upon clarification and subsequent downstream chromatography steps. Flocculation is a simple method to pre-clarify high density Chinese hamster ovary (CHO) cell culture feed streams, allowing for an efficient clarification process that would otherwise not be feasible using traditional depth filters. Clarisolve® mPAA polymer is a stimulus-responsive flocculation polymer that may provide a reduced dosing dependency and lower residual polymer levels when compared to other flocculants. Cell culture pre-treatment with Clarisolve® mPAA polymer followed by clarification using Clarisolve® 60HX depth filters, enables a significant increase of harvest throughputs and allows for a single clarification stage for these high-density feed streams. Furthermore, by eliminating the need for centrifugation, pre-treatment with Clarisolve® mPAA polymer allows for the implementation of a single-use clarification train.This webinar will review the efficacy of pretreatment with a range of Clarisolve® mPAA polymer concentrations upon the clarification and purification of a CHO cell culture feed stream. These results were compared to material prepared using conventional Millistak+® HC depth filtration media to deliver a comprehensive, holistic assessment of the effects of Clarisolve® mPAA polymer pre-treatment upon the clarification and subsequent downstream chromatography steps. In this webinar, you will learn more about:
|
Overview of the Regulatory Landscape for Plastic Devices in Pharmaceutical Manufacturing
|
Abstract: This webinar highlights regulations for plastic devices in pharmaceutical manufacturing, a risk-based approach to qualifying components, and the importance of regulatory documentation. The growing complexity of therapeutics and globalization are some of the factors leading to innovative manufacturing solutions. Thanks to their flexibility and ease of use, polymeric materials are being used more frequently in the manufacturing of pharmaceuticals and biopharmaceuticals. Consequently, the development and qualification of plastic components requires a purposeful implementation of a multifaceted regulatory guidance. However, the lack of regulations specific to plastics used in pharmaceutical manufacturing systems has led to considerable uncertainty. In this webinar, you will learn:
|
Identifying Appropriate-Quality Pharmaceutical Raw Materials in an Evolving Regulatory Environment
Session 1: 3:00 AM EST, 12 AM PST, 9 AM CET View your Time Zone start time
Register Now Session 2: 11:00 AM EST, 8 AM PST, 5 PM CET View your Time Zone start time
Register Now |
Abstract: This webinar will discuss appropriate quality attributes for different raw material uses, present strategies to support identification, selection and risk assessment of raw materials, and highlight the importance of regulatory documentation. Recent and continuing regulatory improvements require drug manufacturers to assess and mitigate risk throughout their entire processes. This includes raw materials used at every stage of manufacturing and clinical phases. Current regulatory guidelines and industry standards clearly define quality requirements for raw materials that are incorporated into, or used close to, final drug product, for example active ingredients and excipients. However, no such clear standards are defined for chemicals used earlier in the process, such as in upstream bioprocessing, early chemical synthesis stages, or clean-in-place. The absence of such standards presents a challenge to efficiently and effectively source raw materials with appropriate supply chain transparency and control, accompanied by the necessary supporting documentation. In this webinar, you will learn:
|